Orchid Pharma gets EMA approval for Exblifep
Exblifep has received EMA's recommendation for marketing authorization for use in treatment of complicated urinary tract infections (cUTI), pneumonia, and bacteremia due to ESBL producing pathogens
Orchid Pharma’s antibiotic invention, ‘Exblifeb,’ which incorporates Enmetazobactam, a beta lactamase inhibitor, has received the European Medicines Agency’s (EMA) recommendation for marketing authorisation.
Designed to address anti-microbial resistance (AMR), ‘Exblifeb’ demonstrates efficacy in treating complicated urinary tract infections (cUTI), pneumonia, and bacteremia caused by extended spectrum beta-lactamase producing pathogens. The company informed that during clinical trials, ‘Exblifeb’ exhibited superior performance compared to the current go-to drug, Piperacillin + Tazobactam. It is positioned as a potent, cost-effective, and Carbapenem-sparing therapy, offering a viable solution in the fight against rising AMR.
Enmetazobactam was invented in India by Orchid and then out-licensed to Allecra Therapeutics for further development.
- Advertisement -